The third batch of centralized procurement in Zhejiang is on the way!

[Pharmaceutical Network Market Analysis] Recently, Zhejiang Provincial Pharmaceutical Equipment Purchasing Center issued the "Zhejiang Provincial Public Medical Institutions Third Batch of Centralized Drug Procurement Documents" (Draft for Comments), according to information from the Internet, this centralized procurement may affect 22 varieties, 400 million market
.

According to the recently circulated volume notification, this centralized procurement includes 20 chemical drugs such as lansoprazole and leuprolide, and 2 of the first batch of unrenewed varieties.
The sales scale of hospital terminals has accumulated to 400 million yuan
.

From the perspective of the treatment categories of these 22 varieties, the digestive system and metabolic drugs are the main ones, accounting for nearly half of the number.
In addition, cardiovascular and cerebrovascular drugs, systemic anti-infective drugs, anti-tumor and immunomodulatory agents, There are also several varieties of nervous system drugs
.

The market capacity of some of the varieties to be collected is relatively large, which is worthy of attention
.

For example, betahistine, a drug for the treatment of vertigo of different causes, data from Minet.
com shows that the market capacity of betahistine has increased from 336 million yuan to 987 million yuan from 2015 to 2019.
At present, the market is still showing a rapid growth trend, reaching 10 billions of dollars
.

Another example is lansoprazole used for bleeding stomach, duodenal ulcer, acute stress ulcer, and acute gastric mucosal injury that are not suitable for oral therapy.
According to the data of Minenet, in 2020, the number of lansoprazole in urban public hospitals, counties and Among the terminal types of peptic ulcer medicines in public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), the sales of lansoprazole exceeded 3 billion yuan
.

In addition, according to the data of Minet, the sales scale of leuprolide in China has also shown a steady growth trend in recent years, which has increased from 580 million yuan in 2013 to 3.
348 billion yuan in 2020
.

This variety is a gonadotropin-releasing hormone analog, which is mainly used in clinical endometriosis; uterine fibroids with menorrhagia, lower abdominal pain, low back pain and anemia; premenopausal breast cancer, and estrogen receptors positive patient; prostate cancer; central precocious puberty
.

Judging from the over-evaluation of the products to be included in the third batch of centralized collection (including the approval of the new registration category), there are many companies that have over-evaluated amoxicillin sodium and clavulanate potassium for injection, and the number is 5, including North China Pharmaceutical, Suzhou Erye Pharmaceuticals, Ruiyang Pharmaceuticals, Lukang Pharmaceuticals, Weikang Pharmaceuticals, etc.
, and a number of supplementary applications for consistency evaluation of companies such as Beite Pharmaceuticals, Kelun Pharmaceuticals, Sinopharm Group, and Sichuan Pharmaceutical Preparations are under review Approval is underway
.

According to data from Minet.
com, in 2021, the sales of terminal amoxicillin-clavulanate potassium injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 3 billion yuan, a year-on-year increase of 12.
13 yuan.
%
.

Since then, the varieties that have been reviewed more are triptorelin acetate injection, lactulose oral solution, etc.
, and the number of companies that have been reviewed is 1, and most of the remaining varieties have not yet been reviewed by companies
.

It is understood that as of now, Zhejiang Province has carried out two batches of provincial centralized procurement, and a total of 31 drugs have been included.
In 2021, the total sales of public hospital terminals in the province will be about 400 million yuan
.

From the perspective of time arrangement, the first two batches of provincial centralized procurement are released in October each year for comments, the list of the proposed varieties will be announced in December, and the results of the selection will be announced in January of the following year
.

The third batch of this year's centralized procurement released the "Notice of Reported Volume" in August.
The industry expects that the bid opening date of this batch of centralized procurement is expected to be earlier, or to set aside sufficient time for the eighth batch of centralized procurement organized by the state and the national medical insurance negotiation in 2022.
preparation time
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.